Hemminki A - Search Results

1

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.

Havunen R, Siurala M, Sorsa S, Grönberg-Vähä-Koskela S, Behr M, Tähtinen S, Santos JM, Karell P, Rusanen J, Nettelbeck DM, Ehrhardt A, Kanerva A, Hemminki A. Havunen R, et al. Among authors: hemminki a. Mol Ther Oncolytics. 2016 Dec 31;4:77-86. doi: 10.1016/j.omto.2016.12.004. eCollection 2017 Mar 17. Mol Ther Oncolytics. 2016. PMID: 28345026 Free PMC article.

2

Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.

Mahasreshti PJ, Navarro JG, Kataram M, Wang MH, Carey D, Siegal GP, Barnes MN, Nettelbeck DM, Alvarez RD, Hemminki A, Curiel DT. Mahasreshti PJ, et al. Among authors: hemminki a. Clin Cancer Res. 2001 Jul;7(7):2057-66. Clin Cancer Res. 2001. PMID: 11448924

3

Transcriptional targeting for ovarian cancer gene therapy.

Casado E, Nettelbeck DM, Gomez-Navarro J, Hemminki A, Gonzalez Baron M, Siegal GP, Barnes MN, Alvarez RD, Curiel DT. Casado E, et al. Among authors: hemminki a. Gynecol Oncol. 2001 Aug;82(2):229-37. doi: 10.1006/gyno.2001.6305. Gynecol Oncol. 2001. PMID: 11531272 Review.

4

Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.

Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT. Kanerva A, et al. Among authors: hemminki a. Clin Cancer Res. 2002 Jan;8(1):275-80. Clin Cancer Res. 2002. PMID: 11801569

5

Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.

Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I, Krasnykh V, Mikheeva GV, Barnes MN, Alvarez RD, Dall P, Alemany R, Curiel DT, Hemminki A. Bauerschmitz GJ, et al. Among authors: hemminki a. Cancer Res. 2002 Mar 1;62(5):1266-70. Cancer Res. 2002. PMID: 11888888

6

The flt-1 promoter for transcriptional targeting of teratocarcinoma.

Bauerschmitz GJ, Nettelbeck DM, Kanerva A, Baker AH, Hemminki A, Reynolds PN, Curiel DT. Bauerschmitz GJ, et al. Among authors: hemminki a. Cancer Res. 2002 Mar 1;62(5):1271-4. Cancer Res. 2002. PMID: 11888889

7

Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv.

Arafat WO, Gómez-Navarro J, Buchsbaum DJ, Xiang J, Wang M, Casado E, Barker SD, Mahasreshti PJ, Haisma HJ, Barnes MN, Siegal GP, Alvarez RD, Hemminki A, Nettelbeck DM, Curiel DT. Arafat WO, et al. Among authors: hemminki a. Gene Ther. 2002 Feb;9(4):256-62. doi: 10.1038/sj.gt.3301639. Gene Ther. 2002. PMID: 11896464

8

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.

Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A. Kanerva A, et al. Among authors: hemminki a. Mol Ther. 2002 Jun;5(6):695-704. doi: 10.1006/mthe.2002.0599. Mol Ther. 2002. PMID: 12027553 Free article.

9

Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.

Haviv YS, Blackwell JL, Kanerva A, Nagi P, Krasnykh V, Dmitriev I, Wang M, Naito S, Lei X, Hemminki A, Carey D, Curiel DT. Haviv YS, et al. Among authors: hemminki a. Cancer Res. 2002 Aug 1;62(15):4273-81. Cancer Res. 2002. PMID: 12154029

10

CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses.

Hakkarainen T, Hemminki A, Pereboev AV, Barker SD, Asiedu CK, Strong TV, Kanerva A, Wahlfors J, Curiel DT. Hakkarainen T, et al. Among authors: hemminki a. Clin Cancer Res. 2003 Feb;9(2):619-24. Clin Cancer Res. 2003. PMID: 12576427

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

348 results

Search Page

Filters